Infants with a specific leukemia genetic change
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a treatment plan for babies under 1 year with leukemia that has a KMT2A gene rearrangement. It may help by trying to improve outcomes in this high-risk group, sometimes using a drug called blinatumomab (depending on eligibility).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is younger than 1 year when leukemia is first diagnosed
- The leukemia is B-cell ALL or a B-cell type mixed phenotype ALL
- Testing shows a KMT2A gene rearrangement (not the KMT2A “wild type”)
- The study team has received consent from a parent or legal guardian
- Your child does NOT have T-cell leukemia (T-ALL) or a relapsed (came back) leukemia
- Your child has not had certain recent treatments like high-dose steroids or chemotherapy before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests two drugs (blinatumomab and revumenib) given together for people with a type of acute lymphoblastic leukemia (ALL) that has a specific genetic change called KMT2A. The combination aims to kill leukemia cells and may be an option for people whose leukemia has returned or not improved, or for older or less fit adults newly diagnosed.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.